FR2846653B1 - Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations - Google Patents

Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations

Info

Publication number
FR2846653B1
FR2846653B1 FR0213607A FR0213607A FR2846653B1 FR 2846653 B1 FR2846653 B1 FR 2846653B1 FR 0213607 A FR0213607 A FR 0213607A FR 0213607 A FR0213607 A FR 0213607A FR 2846653 B1 FR2846653 B1 FR 2846653B1
Authority
FR
France
Prior art keywords
inhibitors
preparation
cyclic nucleotide
nucleotide phosphodiesterases
phosphodiesterases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0213607A
Other languages
English (en)
Other versions
FR2846653A1 (fr
Inventor
Jean Jacques Bourguignon
Claire Lugnier
Mustapha Abarghaz
Yan Lagouge
Patrick Wagner
Cesare Mondadori
Jean Paul Macher
Dominique Schultz
Pierre Raboisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuro3D SA
Original Assignee
Neuro3D SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0213607A priority Critical patent/FR2846653B1/fr
Application filed by Neuro3D SA filed Critical Neuro3D SA
Priority to NZ540167A priority patent/NZ540167A/en
Priority to DE60324449T priority patent/DE60324449D1/de
Priority to EP03780257A priority patent/EP1556055B1/fr
Priority to JP2005502123A priority patent/JP2006509832A/ja
Priority to US10/533,157 priority patent/US20060128695A1/en
Priority to PCT/FR2003/003247 priority patent/WO2004041258A2/fr
Priority to AT03780257T priority patent/ATE412415T1/de
Priority to ES03780257T priority patent/ES2315546T3/es
Priority to CA002503716A priority patent/CA2503716A1/fr
Priority to AU2003288352A priority patent/AU2003288352A1/en
Publication of FR2846653A1 publication Critical patent/FR2846653A1/fr
Priority to ZA200505412A priority patent/ZA200505412B/en
Application granted granted Critical
Publication of FR2846653B1 publication Critical patent/FR2846653B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0213607A 2002-10-30 2002-10-30 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations Expired - Fee Related FR2846653B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0213607A FR2846653B1 (fr) 2002-10-30 2002-10-30 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
ES03780257T ES2315546T3 (es) 2002-10-30 2003-10-30 Inhibidores delas fosfodiesterasas de los nucleotidos ciclicos, que presentan una estructura de benzodiazepina, y su uso en terapia.
EP03780257A EP1556055B1 (fr) 2002-10-30 2003-10-30 Inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique, et leur utilisation en therapie
JP2005502123A JP2006509832A (ja) 2002-10-30 2003-10-30 サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
US10/533,157 US20060128695A1 (en) 2002-10-30 2003-10-30 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
PCT/FR2003/003247 WO2004041258A2 (fr) 2002-10-30 2003-10-30 Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
NZ540167A NZ540167A (en) 2002-10-30 2003-10-30 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
DE60324449T DE60324449D1 (de) 2002-10-30 2003-10-30 Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
CA002503716A CA2503716A1 (fr) 2002-10-30 2003-10-30 Utilisation d'inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
AU2003288352A AU2003288352A1 (en) 2002-10-30 2003-10-30 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
AT03780257T ATE412415T1 (de) 2002-10-30 2003-10-30 Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
ZA200505412A ZA200505412B (en) 2002-10-30 2005-05-27 Cyclic nucleotide phosphodiestierase inhibitors, preperation and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0213607A FR2846653B1 (fr) 2002-10-30 2002-10-30 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations

Publications (2)

Publication Number Publication Date
FR2846653A1 FR2846653A1 (fr) 2004-05-07
FR2846653B1 true FR2846653B1 (fr) 2007-04-20

Family

ID=32104322

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0213607A Expired - Fee Related FR2846653B1 (fr) 2002-10-30 2002-10-30 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations

Country Status (2)

Country Link
FR (1) FR2846653B1 (fr)
ZA (1) ZA200505412B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
CN112194667B (zh) * 2020-11-06 2021-08-17 湖南科技大学 取代1,4-苯并噁嗪并二氮卓类化合物及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1145626B (de) * 1959-12-10 1963-03-21 Hoffmann La Roche Verfahren zur Herstellung von 3H-1, 4-Benzodiazepin-2(1H)-on-derivaten
DE1136709B (de) * 1959-12-10 1962-09-20 Hoffmann La Roche Verfahren zur Herstellung von 2-Oxo-1, 2-dihydro-1, 4-benzodiazepinen
US3515755A (en) * 1968-06-18 1970-06-02 Hoffmann La Roche Lower alkanoyl amido benzophenones
US3609146A (en) * 1968-11-01 1971-09-28 Sandoz Ag Substituted benzodiazepinone derivatives
US3573282A (en) * 1969-03-27 1971-03-30 Upjohn Co 4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-diones
DE1942744A1 (de) * 1969-08-22 1971-03-04 Cassella Farbwerke Mainkur Ag 2-Imino-1,2-dihydro-3H-1,4-benzodiazepine und Verfahren zu ihrer Herstellung
US3778433A (en) * 1969-04-18 1973-12-11 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
GB1346176A (en) * 1970-08-25 1974-02-06 American Home Prod Benzodiazepines
US3803129A (en) * 1972-08-10 1974-04-09 American Home Prod 1,5-dihydro-3-alkoxy-5-phenyl-2h-1,4-benzodiazepin-2-ones
US4056525A (en) * 1975-06-02 1977-11-01 American Home Products Corporation 2,3-dialkoxy-3h-1,4-benzodiazepines
JPS54157585A (en) * 1978-05-30 1979-12-12 Yasumitsu Tamura Manufacture of 1*44benzodiazepin
PH26955A (en) * 1989-03-08 1992-12-03 Kali Chemie Pharma Gmbh Novel 1,7-fused 1H-indole-2-carboxylic acid N-(1,4-benzodiazepin-3-YL) amides
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
WO2002098865A2 (fr) * 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs

Also Published As

Publication number Publication date
FR2846653A1 (fr) 2004-05-07
ZA200505412B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
IL159105A0 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2002252183A1 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
DK3587433T3 (da) Modificerede nukleotider
AU2003256619A8 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
EP1556399A4 (fr) Derives de nucleosides utilises en tant qu'inhibiteurs de l'arn polymerase virale arn-dependante
DK2354148T3 (da) Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
DE69811645T2 (de) Phtalazinonen
IL180933A0 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
NO20070263L (no) Immunostimulerende oligonukleotidmultimerer
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
DK1523489T3 (da) Modificerede 2'- og 3'-nukleosidprodrugs til behandling af flaviridae-infektioner
NO20052058D0 (no) Behandling av influensa.
HUP0400726A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EE200200426A (et) PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
MXPA04012614A (es) Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
IL176478A0 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
ATE333463T1 (de) Selektive dipeptidische inhibitoren von kallikrein
WO2005115410A3 (fr) Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes
EP1816130A4 (fr) Nouveau derive de nucleoside ou de nucleotide et son utilisation
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
AU2003260945A8 (en) Methods of use for thermostable rna ligases
EP1513402A4 (fr) Inhibiteurs ameliores d'adp-ribosyl transferases, cyclases, et hydrolases

Legal Events

Date Code Title Description
TQ Partial transmission of property
TQ Partial transmission of property
AU Other action affecting the ownership or exploitation of an industrial property right
TP Transmission of property
AU Other action affecting the ownership or exploitation of an industrial property right
ST Notification of lapse

Effective date: 20100630